Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...

Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be released ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.32 billion focused on developing and commercializing new medicines for difficult-to-treat cancers, has been ...

Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $40.00 target ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...

A major downgrade, a billion-dollar pipeline gamble, and a patent war--Exelixis investors brace for a wild ride.

Stephens reiterated their equal weight rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research report report ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

Oppenheimer shifts to a neutral stance on Exelixis, questioning differentiation between zanzalintinib and cabozantinib ...